Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today announces that the first patient in the United States (U.S.) has been dosed in BiPASS™ (Bi opsy of the P rostate A voidance S ...
University Hospitals Seidman Cancer Center researchers have developed a tool that could identify metastatic prostate cancer ...
Vietnam Investment Review on MSN
BiPASS prostate cancer study begins patient dosing
MELBOURNE, Australia and INDIANAPOLIS, Jan. 16, 2026 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") today announces that the first patient in the United States (U.S.) ...
A LOCAL councillor has raised serious concerns about the ongoing lack of effective access to the Rapid Access Prostate Clinic ...
A polygenic risk score was able to detect a high proportion of clinically significant prostate cancer. Cancer would not have been detected in 71.8% of patients with the use of PSA or MRI screening.
A University of Kentucky Markey Cancer Center study reveals how prostate cancer cells adapt their metabolism to thrive in bone tissue, offering a potential new treatment target for patients with ...
An integrated strategy for the prevention, support and treatment of prostate cancer was launched today. The plan, which was the result of collaborative efforts by the Ministry of Health, the Bermuda ...
Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") today announces that the first patient in the United States (U.S.) has been dosed ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback